Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verrica Pharmaceuticals (VRCA) Interest Expenses (2021 - 2025)

Verrica Pharmaceuticals (VRCA) has 5 years of Interest Expenses data on record, last reported at $1.3 million in Q4 2025.

  • For Q4 2025, Interest Expenses fell 44.06% year-over-year to $1.3 million; the TTM value through Dec 2025 reached $7.7 million, down 17.74%, while the annual FY2025 figure was $7.7 million, 17.74% down from the prior year.
  • Interest Expenses reached $1.3 million in Q4 2025 per VRCA's latest filing, down from $2.1 million in the prior quarter.
  • Across five years, Interest Expenses topped out at $2.4 million in Q3 2024 and bottomed at -$57000.0 in Q4 2022.
  • Average Interest Expenses over 5 years is $1.5 million, with a median of $1.5 million recorded in 2023.
  • Peak YoY movement for Interest Expenses: plummeted 105.2% in 2022, then skyrocketed 4143.86% in 2023.
  • A 5-year view of Interest Expenses shows it stood at $1.1 million in 2021, then tumbled by 105.2% to -$57000.0 in 2022, then surged by 4143.86% to $2.3 million in 2023, then rose by 1.91% to $2.3 million in 2024, then crashed by 44.06% to $1.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Interest Expenses were $1.3 million in Q4 2025, $2.1 million in Q3 2025, and $2.1 million in Q2 2025.